B
Bernhard Manger
Researcher at University of Erlangen-Nuremberg
Publications - 254
Citations - 11190
Bernhard Manger is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Medicine & Arthritis. The author has an hindex of 49, co-authored 229 publications receiving 9557 citations.
Papers
More filters
Journal Article
Musculoskeletal ultrasound including definitions for ultrasonographic pathology
Richard J. Wakefield,Peter V. Balint,Marcin Szkudlarek,Emilio Filippucci,Marina Backhaus,Maria Antonietta D'Agostino,Esperanza Naredo Sanchez,Annamaria Iagnocco,Wolfgang A. Schmidt,George A W Bruyn,David Kane,Philip O'Connor,Bernhard Manger,Fred Joshua,Juhani M. Koski,Walter Grassi,Marissa Lassere,Nanno Swen,Franz Kainberger,Andrea Klauser,Mikkel Østergaard,Andrew K. Brown,Klaus P Machold,Philip G. Conaghan +23 more
TL;DR: The first report from the OMERACT ultrasound special interest group is presented, which has compared US against the criteria of the O MERACT filter, and for the first time are consensus US definitions for common pathological lesions seen in patients with inflammatory arthritis.
Journal ArticleDOI
Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines
Christine Schauer,Christina Janko,Luis E. Muñoz,Yi Zhao,Deborah Kienhöfer,Benjamin Frey,Michael Lell,Bernhard Manger,Jürgen Rech,Elisabeth Naschberger,Rikard Holmdahl,Veit Krenn,Thomas Harrer,Ivica Jeremic,Rostyslav Bilyy,Georg Schett,Markus H. Hoffmann,Martin Herrmann +17 more
TL;DR: It is reported that neutrophils recruited to sites of inflammation undergo oxidative burst and form neutrophil extracellular traps (NETs), and aggregated NETs promote the resolution of neutrophilic inflammation by degrading cytokines and chemokines and disrupting neutrophIL recruitment and activation.
Journal ArticleDOI
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
C Antoni,Arthur Kavanaugh,B. Kirkham,Zuhre Tutuncu,Gerd R Burmester,Udo Schneider,Daniel E. Furst,Jerry A. Molitor,Edward C. Keystone,Dafna D. Gladman,Bernhard Manger,Siegfried Wassenberg,Ralf Weier,Daniel J. Wallace,Michael H. Weisman,Joachim R. Kalden,Josef S Smolen +16 more
TL;DR: Therapy with infliximab at a dose of 5 mg/kg significantly improved the signs and symptoms of arthritis, psoriasis, dactylitis, and enthesitis in patients with active PsA that had been resistant to DMARD therapy.
Journal ArticleDOI
Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus.
Irith Baumann,Wasilis Kolowos,Reinhard E. Voll,Bernhard Manger,Udo S. Gaipl,Winfried Neuhuber,Thomas Kirchner,Joachim R. Kalden,Martin Herrmann +8 more
TL;DR: It is suggested that in a sub-group of SLE patients, apoptotic cells are not properly cleared by tingible body macrophages of the GCs, and nuclear autoantigens bind to FDCs and may thus provide survival signals for autoreactive B cells.
Journal ArticleDOI
Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies
Arnd Kleyer,Stephanie Finzel,Jürgen Rech,Bernhard Manger,Manuel Krieter,Francesca Faustini,Elisabeth Araujo,Axel J. Hueber,Ulrike Harre,Klaus Engelke,Georg Schett +10 more
TL;DR: The concept that bone damage is an exclusive consequence of synovitis in patients with RA is revised, as structural bone damage starts before the clinical onset of arthritis in subjects with ACPA.